Initial results of patients with early-stage prostate cancer on active holistic surveillance.

• DOI: 10.1200/jco.2016.34.2_suppl.19
• Publication Date: 2017-02-24T10:56:38Z
• Authors: Aaron Katz; Andrew S Fontes; Kaitlin E. Kosinski
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

19 Background: There is currently no consensus on how active surveillance should be utilized in order to optimize the benefit of patients with prostate cancer (PCa) prevent overtreatment. Our institution’s protocol, known as Active Holistic Surveillance (AHS) integrates MRI screening place serial biopsies. Nutritional supplements and lifestyle changes are also suggested provide a holistic way reduce progression. We look compare definitive treatment rates our cohort AHS other publications literature. Methods: A retrospective chart review was conducted 200 placed for low low-intermediate risk PCa under D’Amico criteria from February 2002 July 2015. Enrollment defined by clinical stage (T1c), PSA 20 ng/mL, diagnosis Gleason 6 or 7 tumor volume >50%, doubling time greater than 1 year. The main objective study evaluate rate discontinuing receive therapy reasons leaving protocol. Results: (age 44-84 years) have median follow-up 40 months (range 4-161). total 24 out (12%) moved treatment. For before 2010 until 2012, were 0%. In 2013, 8 (4%) received 2014, 12 (6%) 2015, 4 (2%) date.The average per year 4%. Reasons included biopsy progression (16.67%), (29.17%), confirmation patient preference (20.83%), deceased due an unrelated illness (4.17%). Conclusions: Low discontinuation compared literature demonstrate that can successful protocol low-risk patients, approach beneficial patients.